论文部分内容阅读
目的本文比较常规剂量和大剂量ＶＩＰ方案化疗对小鼠Ｌｅｗｉｓ肺癌的疗效，同时分析应用体外扩增的骨髓细胞进行移植治疗的可行性。方法骨髓细胞采用微血管内皮细胞共培养方法进行体外培养扩增。Ｃ５７ＢＬ／６Ｊ小鼠皮下接种１×１０６Ｌｅｗｉｓ肺癌细胞，接种后第３天和第１４天分别进行常规剂量和大剂量ＶＩＰ方案化疗。常规剂量ＶＩＰ方案（ＶＩＰＣＤ）为顺铂（４ｍｇ／ｋｇ，腹腔注射，第１天），异环磷酰胺（２００ｍｇ／ｋｇ，腹腔注射，第２天）和依托帕甙（２ｍｇ／ｋｇ，腹腔注射，第１～２天）。大剂量ＶＩＰ方案（ＶＩＰＨＤ）是将上述药物的剂量分别提高２．５倍，用法同上。ＶＩＰＨＤ化疗后２４ｈ经尾静脉移植３×１０６体外扩增的骨髓细胞。采用定期测量肿瘤体积和随访小鼠生存时间进行疗效评定。结果对早期肿瘤（接种后３天，平均肿瘤直径为０．５ｃｍ），ＶＩＰＣＤ化疗明显抑制肿瘤生长；但对接种后２周的巨大肿瘤（平均肿瘤直径１．５ｃｍ），应用该方案间隔２周连续治疗３个疗程仍不能有效控制肿瘤生长。上述实验中ＶＩＰＣＤ治疗组的中位生存期与对照组相比无统计学显著差异（Ｐ＞０．０５）。与此相反，单次ＶＩＰＨＤ化疗和骨髓移植显著控制了早期肿瘤生长，使治愈率达到９?
Objective To compare the efficacy of routine and high-dose VIP chemotherapy in the treatment of Lewis lung cancer in mice and to analyze the feasibility of using bone marrow cells expanded in vitro for transplantation. Methods Bone marrow cells were cultured and expanded in vitro using microvascular endothelial cell co-culture method. C57BL/6J mice were inoculated subcutaneously with 1×10 6 Lewis lung cancer cells, and conventional and large dose VIP chemotherapy were performed on the 3rd and 14th days after inoculation. The conventional dose VIP regimen (VIPCD) was cisplatin (4 mg/kg, intraperitoneal injection, day 1), ifosfamide (200 mg/kg, intraperitoneal injection, day 2) and etoposide (2 mg/kg, intraperitoneal injection , 1st to 2nd days). The high-dose VIP regimen (VIPHD) increases the dose of the above-mentioned drugs by 2.5 times, respectively, as described above. 24 hours after VIPHD chemotherapy, 3 × 106 in vitro expanded bone marrow cells were transplanted via the tail vein. Efficacy was evaluated by measuring the tumor volume on a regular basis and following the survival time of the mice. Results For early tumors (average tumor diameter 0.5 cm 3 days after inoculation), VIPCD chemotherapy significantly inhibited tumor growth; however, for 2 weeks after inoculation, the giant tumors (average tumor diameter 1.5 cm) were applied at intervals of 2 weeks Three consecutive courses of treatment can not effectively control the growth of tumors. There was no statistically significant difference in median survival between the VIPCD treatment group and the control group (P>0.05). In contrast, a single VIPHD chemotherapy and bone marrow transplantation significantly controlled early tumor growth, resulting in a cure rate of 9?